Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 7Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 92Breast Neoplasms 86Neoplasms 79Prostatic Neoplasms 50Lung Neoplasms 44Neoplasm Metastasis 40Colorectal Neoplasms 37Leukemia, Myeloid, Acute 32Pain 27Head and Neck Neoplasms 25Colonic Neoplasms 25Multiple Myeloma 24Ovarian Neoplasms 23Lymphoma 23Carcinoma, Hepatocellular 23Pancreatic Neoplasms 22Lymphoma, Follicular 21Melanoma 20Leukemia 20Rectal Neoplasms 19Lymphoma, Non-Hodgkin 19Urinary Bladder Neoplasms 17Recurrence 17Stomach Neoplasms 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Squamous Cell Carcinoma of Head and Neck 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Leiomyoma 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Pruritus × Clear all
NCT02811783 2022-10-28

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

Elorac, Inc.

Phase 3 Terminated
59 enrolled
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡